Primary thrombocythemia: a current perspective.
The relationships among thrombocytosis, abnormal platelet aggregation and altered hemostasis in primary thrombocythemia remain poorly understood. Consequently, the appropriate management of asymptomatic patients is controversial and needs to be individualized. For symptomatic patients, conventional therapy, usually hydroxyurea, is directed primarily at lowering the platelet count by suppression of megakaryocyte activity. Recombinant interferon alpha can selectively lower platelet counts and may offer a reasonable alternative. Recent experience with anagrelide is also most promising in both symptomatic and asymptomatic patients. Current thoughts on the pathogenesis and management guidelines are presented here.
Mughal
T I
TI
Department of Medicine, King Fahad National Guard Hospital, Riyadh, Saudi Arabia.
D001241:Aspirin / Q000627:therapeutic use; D003937:Diagnosis, Differential; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007370:Interferon Type I / Q000627:therapeutic use; D009196:Myeloproliferative Disorders / Q000175:diagnosis; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D010983:Plateletpheresis; D011799:Quinazolines / Q000627:therapeutic use; D011994:Recombinant Proteins; D013922:Thrombocytosis / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy
D007370:Interferon Type I; D010975:Platelet Aggregation Inhibitors; D011799:Quinazolines; D011994:Recombinant Proteins; C021139:anagrelide; D001241:Aspirin; D006918:Hydroxyurea